GJC2抗体—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 30 μg, Lane: OP9 cells, Primary antibody: P10786(GJC2 Antibody) at dilution 1/450, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

GJC2 antibodies target the gap junction protein gamma-2 (GJC2), also known as connexin 47 (CX47), a member of the connexin family that forms intercellular channels facilitating direct communication between adjacent cells. GJC2 is predominantly expressed in oligodendrocytes and plays a critical role in central nervous system (CNS) myelination and homeostasis. Mutations in the GJC2 gene are linked to hereditary neurological disorders, such as Pelizaeus-Merzbacher-like disease type 1 (PMLD1) and hypomyelinating leukodystrophy, characterized by impaired myelin formation and neurological deficits.

Research on GJC2 antibodies has focused on elucidating the protein’s structural and functional roles in myelination, gap junction assembly, and oligodendrocyte-astrocyte interactions. These antibodies are widely used in immunohistochemistry, Western blotting, and immunofluorescence to localize GJC2 expression in CNS tissues, assess its distribution under pathological conditions, and study disease mechanisms in animal models. Additionally, GJC2 antibodies have been instrumental in identifying pathogenic mutations and evaluating therapeutic strategies targeting connexin-related dysfunctions.

Recent studies highlight the potential of GJC2 as a biomarker for leukodystrophies and its involvement in neuroinflammatory processes. However, challenges remain in standardizing antibody specificity across experimental models and understanding how specific GJC2 variants contribute to phenotypic variability in patients. Ongoing research aims to refine diagnostic tools and explore connexin-targeted therapies for demyelinating disorders.